---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-061632"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2025-07-07T23:59:59+00:00"
generated_at: "2026-05-18T09:19:37.566051+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Jasper reports 89% complete response in single-dose CSU cohorts, but drug lot issue delays Phase 2b to mid-2026

## Summary
- 8 of 9 (89%) patients in 240mg and 360mg single-dose cohorts achieved complete response (UAS7=0).
- 8 of 11 (73%) in 180mg Q8W open-label extension achieved complete response at week 12.
- Results from 240mg Q8W and 240mg→180mg Q8W cohorts confounded by drug product lot issue affecting 10 of 13 patients.
- ETESIAN asthma study halted due to same lot issue; SCID development stopped; cost cutting and potential restructuring.
- Additional BEACON data expected Q4 2025; Phase 2b CSU study start delayed to mid-2026.

## SEC filing metadata
- accession: 0001213900-25-061632
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2025-07-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390025061632/0001213900-25-061632-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390025061632/ea0248252-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-061632
- JSON: https://secwatch.observer/filing/0001213900-25-061632.json
- Plain text: https://secwatch.observer/filing/0001213900-25-061632.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.